65,437 trials
Kaposi Sarcoma · Human Immunodeficiency Virus · Immune Reconstitution Syndrome
Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants
Parapneumonic Effusion · Empyema, Pleural · Coagulopathy
Primary: Hospital Length of Stay — 12.4; 8.4 days
Multiple Myeloma · Chronic Kidney Disease
Primary: Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain — 13; 3 Participants — p=0.006
Spinocerebellar Ataxias · Tai Chi
Primary: Scale for the Assessment and Rating of Ataxia(SARA) — 11.5; 9 score on a scale
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
Solid Organ Malignancies · Adenoidcystic Carcinoma · Neuroendocrine Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLT) at Each Dose Level — 3; 3; 5; 3 Participants
Covid19
Primary: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 4; 4; 0 Participants
Primary Immunodeficiency Disease
Primary: Incidence Rate of Acute Serious Bacterial Infections (ABSIs) — 0.0; 0.0 infections per participant-year
Suicidal Ideation · Suicide, Attempted · Mental Health Issue
Primary: Number of Suicidal Ideology (SI) Participants Who Agree to Receive a Safety Plan — 15; 16 Participants
Asthma · Asthma Chronic · Asthma Bronchial
Primary: Total Airway Volume (iVaw) — 49.033; 48.577; 51.101; 50.831 mL — p=0.727
Breast Cancer
Primary: Number of Participants With Surgical Site Infection — 7; 4 participants
Malaria
Primary: Analysis of 14C-Pyronaridine Total Radioactivity in Urine — 0.09; 0.16; 0.60; 0.71 % administered dose
Hematological Malignancies
Primary: Percentage of Participants With Grade II-IV Acute GVHD Between the 2 Groups — 12.2; 8.9 percentage of participants with aGVHD — p=0.508
XMEN
Primary: Participants With a ≥0.5 Log Reduction in the Number of EBV-infected B Cells After Magnesium Supplementation as Compared to Placebo - Phase 1 — 0; 0 Participants
Spinal Cord Injury
Primary: Treatment Self-Regulation for Exercise Scale — 5.75; 5.51; 3.23; 2.63 score on a scale